UPDATE 1-Allergan CEO says company is "weeks away" from closing Teva deal

NEW YORK, May 23 (Reuters) - Allergan Plc Chief Executive Brent Saunders said on Monday the company expects to close the $40.5 billion sale of its generic medicines portfolio to Teva Pharmaceutical Industries Ltd in a matter of weeks, opening the door for new acquisitions.